<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>A monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus .</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the promoter of the ribosomal RNA gene and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the ribosomal RNA promoter and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by anti-LMP-1 antisumption of affinity are the ones indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by polyclonal anti-LMP-1 affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by polyclonal anti-LMP-1 purified affinity antiserum are indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Blots were surveyed with D1 antibody of anti-64kD human autoantigen recognizing a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Blots were surveyed with D1 antibody of human autoantigen anti-64kD recognizing polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Blots were surveyed with most of the regulators belonging to the AraC/XylS family recognizing multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>C-term of CD40 at a 1:500 dilution are recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>C-term of CD40 at a 1:500 dilution will be recognized by the polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>C-term of CD40 at a 1:500 dilution, was unrecognized in immunoprecipitatio with polyclonal anti-CD40 anti-rabbit antisound, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>D1 anti-64kD human autoantigen recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>D1 antibody of anti-64kD human autoantigen has also joined these 727 sites but, unlike NarP, has also recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>D1 antibody of anti-64kD human autoantigen specifically recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>D1 antibody of human autoantigen anti-64kD that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the NarL protein can recognize heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex can recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein has recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit has recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified has recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound has recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminus was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptamers in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where short reasons within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognized heptamers in other arrangements, and by Western blotting</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with a monoclonal antibody which recognized STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with a monoclonal antibody which recognized the STAT1 N-terminal and by the western inflorescence.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating the cAMP-CRP complex which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-Stat3 pAb which recognized the lowest form of Stat3, Stat3Beta and by the western inflorescence.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminal and by the western inflorescence.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple connection site and by the western inflorescence.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multiple linkage site, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-CD40 anti-rabbit antisound which recognized C-term of CD40 at a 1:500 dilution and by the western inflorescence.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognized short reasons within the protected region, and by Western blotting</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognizes short motives within the protected region, and by Western blotting</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognizes short reasons within the protected region, and by Western blotting</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the activator complex cAMP-CRP which recognized two sites in tsx-p2 and by the western inflorescence.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the activator complex cAMP-CRP which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the eukaryotic binding factor upstream (UBF) which recognizes the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognizes the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where STAT1 N-terminus was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where heptamers in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where short motives within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where short reasons within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the promoter of the RNA ribosomal gene was recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the promoter of the RNA ribosomal gene was recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>It is shown that D1 anti-64kD human autoantigen has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>It is shown that NarL protein has recognized heptameric in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>It is shown that NarL protein has recognized heptamers in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>It is shown that anti-64kD antibodies of human autoantigen D1 has recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>It is shown that anti-LMP-1 antisembly purified has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>It is shown that anti-LMP-1 purified affinity antiserum has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>N-terminus STAT1 are recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>N-terminus STAT1 is recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>N-terminus STAT1 is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>N-terminus STAT1 was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>N-terminus STAT1 was recognized in the immunoprecipitatome with monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>N-terminus STAT1, cannot is recognized in immunoprecipitatio with monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>N-terminus STAT1, has been recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>NarL protein also binds to these 727 sites but, unlike NarP, also recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>NarL protein binds to these 727 sites but, unlike NarP, will also recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>NarL protein can recognize heptameric in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>NarL protein is able to recognize heptameric in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>NarL protein recognized heptameric in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>NarL protein recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>NarL protein that recognized heptameric in other arrangements was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that A monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen are able to recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen can recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein are able to recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein can recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein has recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody can recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 can recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 has recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody are able to recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 antisembly purified are able to recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 purified affinity antiserum are able to recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 purified affinity antiserum are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that polyclonal anti-LMP-1 affinity antisumption are able to recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>STAT1 N-terminal are recognized by monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>STAT1 N-terminal were recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>STAT1 N-terminal will be recognized in immunoprecipitatio with monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>STAT1 N-terminal, cannot is recognized in immunoprecipitatio with monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>STAT1 N-terminus are recognized by a monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>STAT1 N-terminus are recognized by a monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>STAT1 N-terminus are recognized by monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>STAT1 N-terminus is recognized by a monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>STAT1 N-terminus is recognized by a monoclonal antibody that the litters were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>STAT1 N-terminus is recognized by monoclonal antibody that the litters were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>STAT1 N-terminus was recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>STAT1 N-terminus was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>STAT1 N-terminus was recognized in the immunoprecipitatome with a monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>STAT1 N-terminus was recognized in the immunoprecipitatome with monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>STAT1 N-terminus were recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>STAT1 N-terminus will be recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>STAT1 N-terminus will be recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>STAT1 N-terminus will be recognized in immunoprecipitatio with monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>STAT1 N-terminus, cannot is recognized in the immunoprecipitaiton with A monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>STAT1 N-terminus, could be recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>STAT1 N-terminus, has been recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>The STAT1 N-terminal was recognized by the monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>The blots were investigated with monoclonal antibody that recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>The blots were investigated with the NarL protein that recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>The blots were investigated with the cAMP-CRP activator complex that recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>The blots were investigated with the upstream eukaryotic binding factor (UBF) that recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>The blots were probed with D1 antibody of human autoantigen anti-64kD that can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>The blots were probed with activating the cAMP-CRP complex that can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>The blots were probed with four different specific antibodies recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>The blots were probed with four different specific antibodies that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The blots were probed with the eukaryotic binding factor upstream (UBF) that can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>The blots were probed with the upstream eukaryotic binding factor (UBF) that can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>The blots were probed with this antibody in PKR+/+MEFs that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>The epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by the anti-LMP-1 purified affinity antiserum that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>The epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by the anti-LMP-1 anti-LMP-1 purified affinity that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>The heptamers in other arrangements is recognized by the the NarL protein that the garbage was surveyed.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>The heptamers in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with A monoclonal antibody that recognizes STAT1 N-terminus and by western blotting.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 antisembly purified that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 and by western blotting.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-Stat3 pAb that recognizes the lowest form of Stat3, Stat3Beta and by western blotting.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with monoclonal antibody that recognizes STAT1 N-terminal and by western blotting.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where N-terminus STAT1 is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where short motives within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where short reasons within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>The multiple binding sites is recognized by the most regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>The multiple connection site was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>The multiple-link location was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by the D1 antibody of human autoantigen anti-64kD acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>The polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>The short reasons within the protected region was recognized by the proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>The the STAT1 N-terminal was recognized by the a monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>The the lowest form of Stat3, Stat3Beta is recognized by the anti-Stat3 pAb that the garbage was surveyed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>The the promoter of the ribosomal RNA gene is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>The two sites in tsx-p2 was recognized by the activator complex cAMP-CRP acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>The two sites in tsx-p2 was recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>The two sites in tsx-p2 was recognized by the the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>We show that A monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>We show that D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>We show that D1 anti-64kD human autoantigen will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>We show that NarL protein recognized heptamers in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>We show that NarL protein will recognize heptameric in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>We show that a monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>We show that activator complex cAMP-CRP recognized two sites in tsx-p2 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 will recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 will recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>We show that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>We show that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>We show that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>We show that anti-LMP-1 antisembly purified will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>We show that monoclonal antibody will recognize STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multi-binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple connection site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple connection site that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple linkage site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple-link location that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple-link location that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple-link location that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>We show that polyclonal anti-LMP-1 affinity antisumption will recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>We show that proteins recognized short motives within the protected region that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>We show that proteins will recognize short motives within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>We show that proteins will recognize short reasons within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>We show that the NarL protein will recognize heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>We show that the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>We show that the upstream eukaryotic binding factor (UBF) will recognize the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>a monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>a monoclonal antibody is able to recognize the STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>a monoclonal antibody that recognizes the STAT1 N-terminal is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>a monoclonal antibody will recognize the STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle are recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle will be recognized in immunoprecipitatio with D1 antibody of anti-64kD human autoantigen, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in immunoprecipitatio with D1 antibody of anti-64kD human autoantigen, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, will be recognized in the immunoprecipitaiton with D1 antibody of anti-64kD human autoantigen as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 that the litters were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle were recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, was not recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>activating complex cAMP-CRP also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>activating complex cAMP-CRP has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>activating the cAMP-CRP complex also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>activating the cAMP-CRP complex can recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>activating the cAMP-CRP complex is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>activating the cAMP-CRP complex that recognized two sites in tsx-p2 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>activator complex cAMP-CRP binds to these 727 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>activator complex cAMP-CRP is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>activator complex cAMP-CRP that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>activator complex cAMP-CRP that recognized two sites in tsx-p2 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>anti-64kD antibodies of human autoantigen D1 binds to these sites 7-2-7, but, unlike NarP, it also recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>anti-64kD antibodies of human autoantigen D1 can recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>anti-64kD antibodies of human autoantigen D1 has also joined these 727 sites but, unlike NarP, has also recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>anti-64kD antibodies of human autoantigen D1 is able to recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit binds to these sites 7-2-7, but, unlike NarP, it also recognizes term C of CD40 at a dilution 1:500 .</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit has also joined these 727 sites but, unlike NarP, has also recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit is able to recognize term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500 in the regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognizes term C of CD40 at a dilution 1:500 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity binds to these 727 sites but, unlike NarP, will also recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity can recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity is able to recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>anti-LMP-1 antisembly purified also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>anti-LMP-1 antisembly purified binds to these sites 7-2-7, but, unlike NarP, it also recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>anti-LMP-1 antisembly purified that has recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>anti-LMP-1 antisembly purified that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>anti-LMP-1 antisembly purified that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>anti-LMP-1 antisembly purified that recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>anti-LMP-1 purified affinity antiserum are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>anti-LMP-1 purified affinity antiserum is able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>anti-LMP-1 purified affinity antiserum that recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>anti-LMP-1 purified affinity antiserum will recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, was not recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, was unrecognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution has been recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized in the immunoprecipitatome with anti-LMP-1 anti-LMP-1 purified affinity, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 could be recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, has been recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, will be recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution are recognized by anti-LMP-1 antisembly purified with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, has been recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, was not recognized in the immunoprecipitaiton with polyclonal anti-LMP-1 affinity antisumption as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized in the immunoprecipitatome with anti-LMP-1 anti-LMP-1 purified affinity, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, cannot is recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>heptameric in other arrangements could be recognized in immunoprecipitatio with NarL protein, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>heptameric in other arrangements is recognized by NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>heptameric in other arrangements, was not recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>heptameric in other arrangements, will be recognized in the immunoprecipitaiton with NarL protein as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>heptamers in other arrangements is recognized by the NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>heptamers in other arrangements was recognized by the NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>heptamers in other arrangements will be recognized by the the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>heptamers in other arrangements, cannot is recognized in the immunoprecipitaiton with NarL protein as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminal .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>monoclonal antibody are able to recognize STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>monoclonal antibody is able to recognize N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>monoclonal antibody that has recognized N-terminus STAT1 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>monoclonal antibody that recognizes N-terminus STAT1 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>monoclonal antibody that recognizes STAT1 N-terminal is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these 727 sites but, unlike NarP, also recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>most of the regulators belonging to the AraC/XylS family are able to recognize multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these 727 sites but, unlike NarP, will also recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these 727 sites but, unlike NarP, will also recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multiple linkage site .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multiple-link location .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>most of the regulators belonging to the AraC/XylS family has also joined these 727 sites but, unlike NarP, has also recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>most of the regulators belonging to the AraC/XylS family that has recognized multi-binding sites was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>most of the regulators belonging to the AraC/XylS family that has recognized multiple linkage site was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multiple connection site is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family that the litters were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>multi-binding sites will be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>multi-binding sites, cannot is recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>multi-binding sites, was not recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>multi-binding sites, will be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>multiple binding sites is recognized by most regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>multiple binding sites is recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>multiple binding sites was recognized by most regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>multiple binding sites, cannot is recognized in immunoprecipitatio with most regulators belonging to the AraC/XylS family, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>multiple binding sites, could be recognized in the immunoprecipitaiton with most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>multiple binding sites, was unrecognized in immunoprecipitatio with most regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>multiple linkage site could be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>multiple linkage site will be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>multiple-link location was recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>multiple-link location will be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>multiple-link location, was not recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>polyclonal anti-CD40 anti-rabbit antisound also binds to these sites 7-2-7, but, unlike NarP, it also recognized C-term of CD40 at a 1:500 dilution .</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>polyclonal anti-CD40 anti-rabbit antisound that has recognized C-term of CD40 at a 1:500 dilution was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>polyclonal anti-CD40 anti-rabbit antisound that recognized C-term of CD40 at a 1:500 dilution was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>polyclonal anti-LMP-1 affinity antisumption also binds to these 727 sites but, unlike NarP, also recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>polyclonal anti-LMP-1 affinity antisumption are able to recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 in regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>polyclonal anti-LMP-1 affinity antisumption specifically recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>polyclonal anti-LMP-1 affinity antisumption that recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen that the litters were probed.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle will be recognized by the D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, could be recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle could be recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized in the immunoprecipitatome with anti-64kD antibodies of human autoantigen D1, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, could be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, was not recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>proteins also binds to these 727 sites but, unlike NarP, also recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>proteins also binds to these sites 7-2-7, but, unlike NarP, it also recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>proteins are able to recognize short motives within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>proteins has also joined these 727 sites but, unlike NarP, has also recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>proteins recognized short reasons within the protected region in the regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>proteins that has recognized short reasons within the protected region was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>proteins that recognized short reasons within the protected region was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>short motives within the protected region are recognized by proteins with which the wires were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>short motives within the protected region is recognized by proteins by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>short motives within the protected region was recognized by proteins by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>short motives within the protected region was recognized in the immunoprecipitatome with proteins, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>short motives within the protected region will be recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>short motives within the protected region will be recognized by the proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>short motives within the protected region will be recognized in immunoprecipitatio with proteins, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>short motives within the protected region, cannot is recognized in immunoprecipitatio with proteins, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>short motives within the protected region, has been recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>short motives within the protected region, was not recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>short reasons within the protected region were recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>short reasons within the protected region, could be recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>term C of CD40 at a dilution 1:500, cannot is recognized in the immunoprecipitaiton with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>term C of CD40 at a dilution 1:500, could be recognized in the immunoprecipitaiton with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>term C of CD40 at a dilution 1:500, was unrecognized in immunoprecipitatio with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>the NarL protein is able to recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>the RNA ribosomal gene promoter were recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>the RNA ribosomal gene promoter, was not recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>the RNA ribosomal gene promoter, was unrecognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>the STAT1 N-terminal is recognized by a monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>the STAT1 N-terminal is recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>the STAT1 N-terminal, could be recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>the STAT1 N-terminal, has been recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>the STAT1 N-terminal, was unrecognized in immunoprecipitatio with a monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>the activator complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2 .</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>the activator complex cAMP-CRP has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>the cAMP-CRP activator complex specifically recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>the eukaryotic binding factor upstream (UBF) can recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene in the regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>the eukaryotic binding factor upstream (UBF) recognizes the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>the lowest form of Stat3, Stat3Beta has been recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>the promoter of the RNA ribosomal gene has been recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>the promoter of the RNA ribosomal gene will be recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>the promoter of the RNA ribosomal gene, was not recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>the promoter of the RNA ribosomal gene, was unrecognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>the promoter of the ribosomal RNA gene is recognized by A0 (monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the screws were sound.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these 727 sites but, unlike NarP, also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the RNA ribosomal gene promoter .</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>the upstream eukaryotic binding factor (UBF) are able to recognize the RNA ribosomal gene promoter in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>the upstream eukaryotic binding factor (UBF) binds to these 727 sites but, unlike NarP, will also recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>the upstream eukaryotic binding factor (UBF) can recognize the RNA ribosomal gene promoter in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>two sites in tsx-p2 has been recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>two sites in tsx-p2 is recognized by the cAMP-CRP activator complex by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>two sites in tsx-p2 was recognized in the immunoprecipitatome with the cAMP-CRP activator complex, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>two sites in tsx-p2 were recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>two sites in tsx-p2 will be recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with activating complex cAMP-CRP, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with the activator complex cAMP-CRP, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>two sites in tsx-p2, cannot is recognized in the immunoprecipitaiton with the activator complex cAMP-CRP as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>two sites in tsx-p2, could be recognized in the immunoprecipitaiton with the activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>two sites in tsx-p2, has been recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with activating the cAMP-CRP complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>two sites in tsx-p2, was unrecognized in immunoprecipitatio with the cAMP-CRP activator complex, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>two sites in tsx-p2, will be recognized in the immunoprecipitaiton with the activator complex cAMP-CRP as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized a number of Ags and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized a series of Ags and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize a series of Ags and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized a number of Ags and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized a series of Ags and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by Class I melanoma-specific T cells are indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the RNA supply apparatus are indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class and T cells specific to melanoma are as given.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autological serum are the ones indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by one of two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the RNA supply apparatus are as given.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the autological serum are as given.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the reverse transcription apparatus are as given.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by one of two monoclonal antibodies are indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the reverse transcription apparatus are indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Blots were surveyed with autologous serum recognizing the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Blots were surveyed with the autological serum recognizing epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>COOH-terminal epitopes are recognized by one of the two monoclonal antibodies with which the wires were probed.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>COOH-terminal epitopes are recognized by one of two monoclonal antibodies with which the threads were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>COOH-terminal epitopes are recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>COOH-terminal epitopes is recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>COOH-terminal epitopes was recognized by one of the two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>COOH-terminal epitopes was recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>COOH-terminal epitopes were recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>COOH-terminal epitopes, cannot is recognized in immunoprecipitatio with one of two monoclonal antibodies, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>COOH-terminal epitopes, will be recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a number of Ags .</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Class I melanoma-specific T cells binds to these sites 7-2-7, but, unlike NarP, it also recognizes a series of Ags .</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Class I melanoma-specific T cells can recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Class I melanoma-specific T cells specifically recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Class and T cells specific to melanoma binds to these 727 sites but, unlike NarP, will also recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Class and T cells specific to melanoma binds to these sites 7-2-7, but, unlike NarP, it also recognizes a series of Ags .</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Class and T cells specific to melanoma that recognizes a series of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Class and T cells specific to melanoma that recognizes a series of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Class and T cells specific to melanoma will recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autological serum can recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum can recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies can recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells has recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum has recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum has recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognized a number of Ags and by the western inflorescence.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognized a number of Ags, and by Western blotting</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class and T cells specific to melanoma which recognized a series of Ags, and by Western blotting</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class and T cells specific to melanoma which recognizes a series of Ags, and by Western blotting</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with RNA supply apparatus which recognizes normal slice ligation, and by Western blotting</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autological serum which recognized epitopes and by the western inflorescence.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the RNA supply apparatus which recognized the normal splice binding and by the western inflorescence.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autological serum which recognized epiptopes and by the western inflorescence.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a series of Ags was recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>It is shown that autological serum has recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma are able to recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma has recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum has recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies are able to recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies can recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies has recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the RNA supply apparatus recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus can recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that Class I melanoma-specific T cells are able to recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that Class and T cells specific to melanoma are able to recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the reverse transcription apparatus are able to recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>RNA supply apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>RNA supply apparatus recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>RNA supply apparatus recognizes normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>The COOH-terminal epitopes is recognized by the one of two monoclonal antibodies that the garbage was surveyed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>The a series of Ags was recognized by the Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>The blots were investigated with RNA supply apparatus that recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>The blots were investigated with class I melanoma-specific T cells that recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>The blots were investigated with one of two monoclonal antibodies that recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>The blots were investigated with the autologous serum that recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>The blots were probed with RNA supply apparatus that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>The blots were probed with one of two monoclonal antibodies recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>The blots were probed with the autological serum that can recognize epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>The epitopes was recognized by the autological serum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>The epitopes was recognized by the the autologous serum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with one of the two monoclonal antibodies that recognizes COOH-terminal epitopes and by western blotting.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the reverse transcription apparatus that recognizes the normal junction of slice and by western blotting.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a series of Ags is recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where cooled-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the normal splice binding is recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>The the epitopes was recognized by the autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>The the normal junction of slice is recognized by the the reverse transcription apparatus that the garbage was surveyed.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>The the normal junction of slice was recognized by the the reverse transcription apparatus acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>These bands can be detected with Class and T cells specific to melanoma that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>These bands can be detected with autological serum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>These bands can be detected with one of two monoclonal antibodies that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>These bands can be detected with the autologous serum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>These bands can be detected with the reverse transcription apparatus that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>We show that Class I melanoma-specific T cells will recognize a number of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>We show that autological serum recognized epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>We show that class I melanoma-specific T cells recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>We show that class I melanoma-specific T cells will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>We show that one of two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>We show that one of two monoclonal antibodies recognized cooled-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>We show that one of two monoclonal antibodies recognized cooled-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>We show that the RNA supply apparatus recognized the normal splice binding that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>We show that the autological serum will recognize epiptopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>We show that the autologous serum recognized epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>We show that the autologous serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>We show that the reverse transcription apparatus recognized the normal junction of slice that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>a number of Ags was recognized in the immunoprecipitatome with Class I melanoma-specific T cells, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>a series of Ags are recognized by Class and T cells specific to melanoma with which the wires were probed.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>a series of Ags are recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>a series of Ags has been recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>a series of Ags has been recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>a series of Ags is recognized by Class I melanoma-specific T cells that the litters were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>a series of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>a series of Ags was recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>a series of Ags were recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>a series of Ags, could be recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>a series of Ags, has been recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>autological serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>autological serum has also joined these 727 sites but, unlike NarP, has also recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>autologous serum recognized epitopes in the regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>autologous serum specifically recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>autologous serum that recognized epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>class I melanoma-specific T cells are able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>class I melanoma-specific T cells binds to these sites 7-2-7, but, unlike NarP, it also recognizes a series of Ags .</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>class I melanoma-specific T cells can recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>class I melanoma-specific T cells has also joined these 727 sites but, unlike NarP, has also recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>cooled-terminal epitopes is recognized by one of two monoclonal antibodies that the litters were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>epiptopes are recognized by the autological serum with which the threads were probed.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>epiptopes are recognized by the autological serum with which the wires were probed.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>epiptopes is recognized by the autological serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>epiptopes was recognized by the autological serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>epiptopes was recognized in the immunoprecipitatome with the autological serum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>epiptopes, has been recognized in the immunoprecipitaiton with the autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>epiptopes, was unrecognized in immunoprecipitatio with the autological serum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>epitopes are recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>epitopes are recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>epitopes is recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>epitopes was recognized in the immunoprecipitatome with autological serum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>epitopes will be recognized by the autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>epitopes will be recognized by the the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>epitopes will be recognized in immunoprecipitatio with autologous serum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>epitopes, could be recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>epitopes, was not recognized in the immunoprecipitaiton with autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>normal slice ligation could be recognized in immunoprecipitatio with RNA supply apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>normal slice ligation is recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>normal slice ligation will be recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>normal slice ligation, cannot is recognized in immunoprecipitatio with RNA supply apparatus, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>one of the two monoclonal antibodies recognized COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>one of the two monoclonal antibodies that recognizes COOH-terminal epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>one of two monoclonal antibodies is able to recognize cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>one of two monoclonal antibodies recognized COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>one of two monoclonal antibodies specifically recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>one of two monoclonal antibodies that recognizes COOH-terminal epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>the RNA supply apparatus are able to recognize the normal splice binding in regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>the RNA supply apparatus has also joined these 727 sites but, unlike NarP, has also recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>the RNA supply apparatus is able to recognize the normal splice binding in regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>the RNA supply apparatus that has recognized the normal splice binding was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>the autological serum also binds to these 727 sites but, unlike NarP, also recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>the autological serum recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>the autological serum recognizes epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>the autologous serum binds to these 727 sites but, unlike NarP, will also recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>the autologous serum specifically recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>the autologous serum that recognizes epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>the epitopes is recognized by autologous serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>the epitopes is recognized by autologous serum that the litters were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>the epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>the epitopes was recognized in the immunoprecipitatome with autologous serum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>the epitopes, will be recognized in the immunoprecipitaiton with autologous serum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>the normal junction of slice are recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>the normal junction of slice is recognized by the reverse transcription apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>the normal splice binding are recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>the normal splice binding is recognized by the RNA supply apparatus that the litters were probed.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>the normal splice binding was recognized in the immunoprecipitatome with the RNA supply apparatus, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>the normal splice binding, has been recognized in the immunoprecipitaiton with the RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>the reverse transcription apparatus also binds to these 727 sites but, unlike NarP, also recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>the reverse transcription apparatus binds to these 727 sites but, unlike NarP, will also recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>the reverse transcription apparatus will recognize the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
